Share chart Mersana Therapeutics, Inc.
Extended chart
Simple chart
About Mersana Therapeutics, Inc.
Mersana Therapeutics, Inc., биофармацевтическая компания клинической стадии, специализирующаяся на разработке конъюгата антитело-лекарственный препарат (ADC) для онкологических больных с неудовлетворенными потребностями. Компания разрабатывает Dolaflexin, платформу, которая используется для создания цепочки запатентованных продуктов-кандидатов ADC, предназначенных для групп пациентов, которые не поддаются лечению с помощью традиционных методов лечения на основе ADC. more details| IPO date | 2017-06-28 |
|---|---|
| ISIN | US59045L1061 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | http://www.mersana.com |
| Цена ао | 0.4481 |
| Change price per day: | 0% (0.4481) |
|---|---|
| Change price per week: | -2.37% (0.459) |
| Change price per month: | -19.49% (0.5566) |
| Change price per 3 month: | -72.34% (1.62) |
| Change price per half year: | -75.78% (1.85) |
| Change price per year: | -90.02% (4.49) |
| Change price per 3 year: | -89.51% (4.27) |
| Change price per 5 year: | -89.84% (4.41) |
| Change price per year to date: | -70.71% (1.53) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| EcoR1 Capital, LLC | 19364688 | 15.96 |
| VR Adviser, LLC | 11328000 | 9.34 |
| Balyasny Asset Management LLC | 9698147 | 7.99 |
| Bain Capital Life Sciences Investors, LLC | 8663673 | 7.14 |
| Blackrock Inc. | 7844282 | 6.47 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 6420136 | 5.29 |
| Vanguard Group Inc | 6237588 | 5.14 |
| Nextech Invest Ag | 5978327 | 4.93 |
| Morgan Stanley | 4134546 | 3.41 |
| Millennium Management LLC | 3394440 | 2.8 |
| ETF | Share, % | Profitability for 1 year, % | Dividends, % |
|---|---|---|---|
| Range Cancer Therapeutics ETF | 0.57886 | 47.24 | 0.11955 |
| iShares Micro-Cap ETF | 0.06221 | 17.09 | 1.54048 |
| Goldman Sachs ActiveBeta US Small Cap Equity ETF | 0.03615 | 31.36 | 1.41955 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
| Vanguard Russell 2000 ETF | 0.01 | 17.16 | 1.48801 |
iShares Russell 2000 Growth ETF
|
0.00947 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.0053 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.00147 | 5.92 | 1.47892 |
| iShares Russell 3000 ETF | 0.00033 | 24.83 | 1.43482 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.07 | 32.64 | 1.16 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Brian C. DeSchuytner | Senior VP, CFO & COO | 626.32k | 1978 (47 years) |
| Mr. Mikhail Papisov Ph.D. | Co-Founder | N/A | |
| Mr. Ashish Mandelia | Chief Accounting Officer | N/A | 1975 (50 years) |
| Mr. Chuck Miller | Senior Vice President of Regulatory Affairs | N/A | |
| Dr. Timothy B. Lowinger Ph.D. | Senior VP and Chief Science & Technology Officer | 666.3k | 1964 (61 year) |
| Ms. Alejandra Veronica Carvajal J.D. | Senior VP, Secretary & Chief Legal Officer | 606.51k | 1974 (51 year) |
| Mr. Jason Fredette | Senior Vice President of Investor Relations & Corporate Communications | N/A | |
| Mr. Marc Damelin | Exe. Director and Head of Biology, Oncology, Antibody-Drug Conjugate ADC Discovery & Develop. | N/A | |
| Dr. Martin H. Huber M.D. | President, CEO & Director | 44k | 1961 (64 years) |
| Mr. Mohan Bala Ph.D. | Senior VP & Chief Development Officer | 1965 (60 years) |
Address: United States, Cambridge, MA , 840 Memorial Drive - open in Google maps, open in Yandex maps
Website: http://www.mersana.com
Website: http://www.mersana.com
